MBX Biosciences, Inc. (MBX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

MBX Biosciences, Inc. (MBX) closed at USD 48.82 on 2026-10-14, a change of +171.8 % over the past year, with a market capitalization of USD 2.44B.

MBX Biosciences, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

MBX Biosciences, Inc. key figures

Previous close

USD 48.82 (2026-10-14)

1-year change

+171.8 %

Market cap

USD 2.44B

Enterprise value

USD 2.03B

P/E ratio (trailing)

-20.70

P/E ratio (forward)

-12.76

EPS (trailing)

-2.45

EPS (forward)

-3.98

PEG ratio

n/a

Price to book

5.94

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

8.58

Employees

63

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About MBX Biosciences, Inc.

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for MBX Biosciences, Inc. and compare it with other stocks.